As GLP-1 treatments become more mainstream and accessible, gyms, fast food companies and other fitness and wellness brands are offering programs and products to support those using weight loss drugs
By Payer Type, Private and Self-Pay Segment Accounts for 70% Market Share Private insurance and self-pay arrangements are projected to contribute 70% of the market in 2025, representing patients who access treatment through commercial health insurance or direct cash payment
Sajad Zalzala, MD, SkinnyRx Medical Director The Future of Oral GLP-1s Oral GLP-1s are much newer, with Rybelsus only receiving FDA-approval in 2019
Journal of Clinical Medicine, 12 (1), 145
In a double-blind, placebo-controlled, phase 2b trial, patients with diabetes were administered all doses of tirzepatide, dulaglutide, or placebo
Retatrutide Weight Loss Treatment Explained Disclaimer This information page is provided for general awareness only